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doi:10.1016/j.asjsur.2012.04.016Summary Objective: Clot embolism remains a concern due to flushing of clot and thrombo-
lytic agent centrally in the process of percutaneous pharmacomechanical thrombolysis (PMT)
for a thrombosed prosthetic arteriovenous access (PAVA), which might be reduced by a modi-
fied technique.
Methods: We retrospectively review this modified technique that uses two balloon-catheters in
crisscross fashion and occludes both ends of PAVA during thrombolysis. Underlying stenotic
lesions were dilated simultaneously with balloon angioplasty when needed.
Results: Among the 23 patients treated, 21 (91.3%), 10 (43.5%), and seven (30.4%) presented
significant stenosis at the outflow, intragraft, and inflow segments of PAVA, respectively.
The median duration of follow-up was 310.0 (range, 288.0e327.0) days. Anatomic success
was achieved in 12 out of 23 (52.2%). Clinical success for successful dialysis was achieved in
all patients. The median primary patency and secondary patency were 126.0 days (range,
7.0e316.0) days and 308.0 days (range, 84.0e327.0), respectively.
Conclusion: We believe this method is safe and effective in dissolving PAVA thrombus as well as
treating culprit stenosis. It may reduce concerns of flushing of clot and thrombolytic agent into
the central circulation in the process of PMT.
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Cross-balloon occlusive thrombolysis/angioplasty 891. IntroductionFigure 1 (A) Drawing the steps of cross-balloon occlusive
thrombolysis for a thrombosed straight forearm prosthetic
arteriovenous access; (B) a 7-French sheath is placed near the
venous end and towards the arterial end and, following a wire,
a dual-lumen Fogarty balloon catheter is advanced to the
arterial anastomosis and inflated. A second 7-French sheath is
then placed within the graft in the opposite direction toward
the venous anastomosis. An appropriately sized angioplasty
balloon is then placed in the same fashion and inflated within
the graft just proximal to the venous anastomotic end; (C) with
the inflation of two balloons simultaneously, a sealed column is
established within the prosthetic graft. Thrombolytic solution
is then introduced slowly into the graft via the side port of one
of the 7-French sheath. Two syringes are used to work alter-
natively in a push-pull fashion (arrows).The outcome of prosthetic arteriovenous access (PAVA)
rescue is very much dependant on both expediency to
salvage procedure and attention to underlying factors that
lead to graft failure. Surgical thrombectomy (ST) alone may
not be adequate for ensuring long-term graft patency
despite short-term success with just thrombus removal per
se.1,2 Increasingly, there is a trend toward using endovas-
cular technique for dialysis access salvage.3 Several phar-
macomechanical thrombolysis (PMT) methodologies4e7
have been developed and demonstrated comparable
outcome of PMT and ST for treatment of PAVA throm-
bosis.8,9 However, there remains a persistent concern with
regards to whether flushing of lytic agent and clot into
central vein during procedure will produce clinically
significant complications.8 The purpose of this study was to
describe a modified hydraulic macerating technique PMT
using two occluding balloons, which allows for clot removal
efficiently hence reducing clot dislodgement centrally
during the salvage procedure.
2. Materials and methods
We obtained approval for the review study from the Far
Eastern Memorial Hospital Research Ethics Committee
(FEMH-97-023). Patients were fully informed of the opera-
tion. We followed the ethical standards of the Helsinki
Declaration in obtaining informed consent and in conduct-
ing the surgical procedures. The exclusion criteria were
contrast medium hypersensitivity, unstable general condi-
tion, graft infection, or ongoing systemic infection.
All salvage procedures were performed in the
angio-suite under local anesthesia listed as “day-case.” In
addition to the PMT, concomitant balloon angioplasty was
performed when needed. A standardized leaflet containing
detailed postoperative instructions was given to each
patient. The techniques of PMT have been described.2,10
The modified technique of cross-balloon occlusive
thrombolysis and angioplasty (CBOTA) is described as
follows (Fig. 1). The midgraft position is marked on the
surface of the graft and anesthetized locally with 2%
Lidocaine. If possible, care is taken not to puncture sites
where repeated needling has been performed for regular
dialysis to avoid areas of possible intragraft stenosis related
to repeated puncturing. Two sheaths are employed in
a crisscrossing but preferably in a nonoverlapping fashion
(Fig. 2). Specifically, following puncture with a 16-gauge
needle near, the venous end and toward the arterial
anastomosis, a guide wire is advanced under fluoroscopy,
after which a 7-French sheath is inserted. A 0.025-in wire is
then advanced under fluoroscopy well beyond the arterial
anastomosis. A dual lumen 4-French Fogarty Thru-Lumen
Embolectomy Catheter (Edwards Lifesciences, Irvine, CA,
USA) is then advanced along the path of the wire. Location
of the arterial anastomosis is then confirmed with ante-
grade angiogram followed by inflation of the contrast-filled
Fogarty balloon within the artery just upstream of the
arterial anastomosis. The inflated balloon can be seen to
deform once it is pulled into the entrance of the graft
hence dislodging the arterial plug into the graft lumen. Asecond 7-French sheath is then placed within the graft in
the opposite direction toward the venous anastomosis. A
scout angiogram is then performed by manipulating
Figure 2 Drawing the ineffective zone when two sheaths are
inserted deeply and overlapped. Treating the in-between
segment (shaded area) will be difficult.
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gram using an imaging catheter to ascertain the extent of
clot formation, if any, beyond the graft-vein junction. An
appropriately sized angioplasty balloon is then placed in
the same fashion as described for the first Fogarty balloon
and inflated within the graft just proximal to the venous
anastomotic end. With the inflation of two balloons simul-
taneously, a sealed column is established within the pros-
thetic graft. A total of 1 million units of urokinase (Taiwan
Green Cross Co., Taipei, Taiwan) dissolved in 40 ml of
heparinized saline is then introduced slowly into the graft
via the side port of one of the 7-French sheath. A hydraulic
pressure is thus set up as the urokinase is pushed into the
fixed volume confined with the graft. An empty syringe is
attached to the side port of the second 7-French sheath as
a column of clot/blood is forced into it as the urokinase is
introduced into the graft. With the establishment of the
hydraulic column, the clot/thrombus within the graft can
be forced out via side ports into the syringes as the action
of “emptying” from one syringe is complemented by
“filling” the other syringe simultaneously. External
compression along the graft could be performed to help
macerate the thrombus. More heparinized saline could be
used as many times as desired to flush out the clots using
the syringes within the fixed column of graft material. The
Fogarty balloon at the arterial end may be pulled further
into the graft to mobilize any residual thrombus likewise for
the angioplastic balloon at the venous end. Contrast can
also be admixed into the final flush to visualize the
completeness of thrombus removal using this modified PMT
technique. The angioplastic balloon proximal to the venous
anastomosis is then released and removed over the wire.
With the other Fogarty balloon still inflated proximal to the
arterial anastomosis, an angiogram is then performed to
visualize the venous outflow. If residual thrombus or
outflow stenosis is visualized, balloon angioplasty is per-
formed accordingly. Once the graft outflow is deemed
satisfactory, the Fogarty balloon at the arterial end is
released and advanced upstream well beyond the arterial
anastomosis to perform an antegrade angiogram. Any
inflow stenosis would then be dealt with accordingly using
balloon angioplasty.
The amount of thrombus in the PAVA was subjectively
estimated by visual determination of contrast opacification
versus intraluminal filling defect. Residual thrombus wasmacerated with either the embolectomy balloon or angio-
plasty balloon. Percutaneous balloon angioplasty was per-
formed when stenoses were detected. Improved luminal
diameter and flow were confirmed by completion digital
subtract imaging.
Sheaths were removed, and hemostasis was achieved by
manual compression and purse-string sutures for 1 hour
postoperatively when needed. Procedure time was calcu-
lated from the first puncture to the completion of hemo-
stasis. Restoration and maintenance of flow were confirmed
with a bruit on auscultation or palpable thrill.
Anatomic success was defined as restoration of flow
combined with a less than 30% maximal residual diameter
stenosis for each segment. Clinical success was defined as
resumption of at least one successful dialysis session.11
Clinical success was obtained by contact with patients,
hemodialysis centers, dialysis nurses, or referring nephrol-
ogists. Primary patency was considered the time between
CBOTA and subsequent intervention or graft failure.
Factors affecting the patency of an access and proce-
dural complications were recorded and graded according to
the reporting standards of the Society for Vascular Surgery
and the American Association for Vascular Surgery.11
Data were presented as median (range) for continuous
variables and number (percentage) for categorical vari-
ables. Events were defined as the development of any
acute complications such as stenosis, thrombosis, or mal-
function requiring intervention during the follow-up period.
All statistical analyses were performed with IBM SPSS
Statistics software (IBM Corp. Armonk, NY).3. Results
In March and April 2008, we developed and treated 23
patients with acute PAVA thrombosis using the CBOTA
method and their charts were retrospectively reviewed.
The demographics and factors related to outcomes are
summarized in Table 1. There were 14 men and nine
women. The median of age of patients was 72.0 years
(range, 51.0e83.0). The median body mass index and body
surface area were 24.8 kg/m (range, 18.4e34.9) and 1.7 m2
(range, 1.4e2.1), respectively. The approximate age of
PAVA was known in 19 out of the 23 and was 18.0 months old
(range 1.0e96.0).
Among the 23 patients evaluated, four had incomplete
factorial data. Out of the 19 patients, 10 (52.6%) had dia-
betes, 16 (84.2%) had hypertension, two (10.5%) used
tobacco, eight (42.1%) had prior documented outflow tract
problems, and 12 (69.6%) experienced prior events of
intervention on the same access.
The clinical results are summarized in Table 2. The
median procedure time was 80.0 minutes (range,
30.0e210.0). The median blood loss was 50.0 ml (range,
10.0e100.0). Out of 23 PAVAs, 21 (91.3%), 10 (43.5%), and
seven (30.4%) presented significant stenosis at the outflow,
intragraft, and inflow segments, respectively. The median
duration of follow-up was 310.0 days (range, 288.0e327.0).
Anatomically decreasing in severity of stenosis by comple-
tion of the graft gram was obtained in 21 out of 23 (91.3%)
and anatomic success was achieved in 12 out of 23 (52.2%);
Moderate residual stenosis in at least one segment was seen
Table 1 Patient profile.
Characteristic Dataa
Men:Women (number) 9:14
Age (yr) 72.0 (51.0e83.0)
BMI (kg/m2) 24.8 (18.4e34.9)
Body surface area (me) 1.7 (1.4e2.1)
Factors affecting outcomeb Grade 1 Grade 2 Grade 3
Diabetes 10/19 (52.6%) 7 3 0
Hypertension 16/19 (84.2%) 4 12 0
Tobacco use 2/19 (10.5%) 2 0 0
Outflow tract 8/19 (42.1%) 6 1 1
Prior procedures on same limb 18/18 (100.0%) 3 7 8
Other factors affecting outcome
Prior thrombosis of same access 12/19 (69.6%)
Age of graft (mo) 18.0 (1.0e96.0)
BMI Z body mass index.
a Data are presented as median (range) for continuous variables and number (percentage) for categorical variables.
b Values indicate number of patients in each category. Grading of severity is presented according to reporting standards of the Society
for Vascular Surgery/American Association for Vascular Surgery.
Table 2 Operative Data and Outcome.
Characteristic Dataa
Procedure time (min) 80.0 (30.0e210.0)
Blood loss (ml) 50.0 (10.0e100.0)
Grading severity of access stenosis before angioplastyb Grade 1 Grade 2 Grade 3
Outlfow stenosis 21/23 (91.3%) 0 13 8
In-graft stenosis 10/23 (43.5%) 0 5 5
Inflow stenosis 7/23 (30.4%) 0 5 2
Maximal stenosis of whole access 22/23 (95.7%) 0 10 12
Grading severity of residual stenosis on completionb Grade 1 Grade 2 Grade 3
Completion outflow stenosis 19/23 (82.6%) 12 6 1
Completion in-graft stenosis 10/23 (43.5%) 7 3 0
Completion inflow stenosis 7/23 (30.4%) 5 2 0
Maximal residual stenosis of whole access 22/23 (95.7%) 11 10 1
Follow-up time (days) 310.0 (288.0e327.0)
Duration to endpoint (days) 308.0 (84.0e327.0)
Grading severity of complicationsc Grade 1 Grade 2 Grade 3
Bleeding 3/23 (13.0%) 1 1 1
Infection 0/23 (0.0%) 0 0 0
Non-infectious fluid collection 0/23 (0.0%) 0 0 0
Anastomotic complications 1/23 (4.3%) 1 0 0
Mid-AV/Runoff vein complications 19/23 (82.6%) 17 2 0
Access thrombosis 12/23 (52.5%) 10 1 1
Access malfunction 0/23 (0.0%) 0 0 0
Steal syndrome 1/23 (4.3%) 1 0 0
Venous hypertension 0/23 (0.0%) 0 0 0
Neuropathy 0/23 (0.0%) 0 0 0
a Data are presented as median (range) for continuous variables and number (percentage) for categorical variables.
b Values indicate number of patients in each category. Anatomic findings and results were determined by angiogram visually and scored
in inflow, intra-graft, and outflow segments as grade 0 for no stenosis, grade 1 for less than 30% diameter reduction with no limitation of
flow, grade 2 for equal or larger than 30% diameter reduction with limitation of flow, and grade 3 for severe residual stenosis or problem
resulting in failure.
c Values indicate number of patients in each category. Grading of severity is presented according to reporting standards of the Society
for Vascular Surgery/American Association for Vascular Surgery.
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dialysis was achieved in all patients. The median event-free
PAVA survival time was 87.0 days (range, 5.0e316.0). The
median primary patency and secondary patency were 126.0
days (range, 7.0e316.0) and 308.0 days (range,
84.0e327.0), respectively.
Table 2 also presents the grading severity of complica-
tions. Among the 23 patients, three (13.0%) presented
unexpected bleeding and one of them required suture
repair and one (4.3%) had mild rupture that happened at
the outflow segment by balloon dilatation but experienced
no residual access malfunction.4. Discussion
This study demonstrates that CBOTA was a feasible and
efficacious option for treatment of PAVA thrombosis. Clin-
ical success and primary patency of CBOTA achieved the
patency goals of 85% of clinical success and 40% primary
unassisted patency at 3 months.12 CBOTA produced
reasonable hydraulic maceration and lacing forces helped
to pulverize the clot effectively.
Clot embolism remains a concern although clot burden
within the thrombosed PAVA is thought to be of low volume.
A close system limited the potential showering of clot and
lytic agents centrally. Experience has shown that the inci-
dence of distant hemorrhage with locally administered
thrombolytic therapy is negligible.7 The “lyse and wait”
technique6,7had been previously described a method of
infusing low dose urokinase into the clotted graft. We
believe the modified method of declotting described in our
series serves to minimize the risk of arterial emboli within
a truly sealed column using two balloons. In addition, the
use of urokinase within sealed tubing also ensures minimal
leakage of urokinase into the systemic circulation thereby
reducing hemorrhagic complications. Although we did not
measure the serum level of thrombolytic agent, most of the
agent mixing with lytic clot in the close column of graft
were pulled out during push-pull procedure and, therefore,
was not infused systemically. No patient experienced
systemic bleeding. Early CBOTA experience translated to
a higher complication rate of post-procedure local bleeding
but predicted noninferior clinical outcome. Three bleeding
events happened locally on the sheath puncture site. Two
of them happened in the postoperating room while
preparing to leave the hospital because we did not place
purse-string sutures when removing sheath in the beginning
series; one of them experienced purse-string-related skin
necrosis due to retention of one purse-string suture for
more than one day accidentally. A close system procedure
also limited blood loss with a median of 50.0 ml, which
included the lytic clot.
Graft gram during CBOTA provided adequate evaluation
of stenosis, which can be corrected by angioplasty in most
instances.3,13 Twenty-two out of 23 (95.7%) patients with
PAVA thrombosis presented at least one significant stenosis
in each access in this series. Anatomical improving was
achieved by balloon dilatation during CBOTA procedure in36 out of 38 (94.7%) diseased segments. One worsening
happened because of rupture.
The limitations of this report include small numbers of
cases, a retrospective single-arm study design, absence of
blinded outcomes assessment, absence of test to see if we
successfully reduced the possibility of pulmonary embo-
lism, and variability in patient follow-up.
In conclusion, CBOTA technique achieved goals of clin-
ical and anatomic success for PAVA thrombosis and provided
adequate short-term patency. It may be an improvement
over current techniques and may reduce concerns of
flushing of clot and thrombolytic agent centrally in the
process of percutaneous thrombolysis. Further follow-up
studies to compare long-term results of varying approaches
is needed.
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